Luke Evnin Net Worth

The estimated Net Worth of Luke Evnin is at least $44.5 Millón dollars as of 6 October 2020. Luke Evnin owns over 151,225 units of Oncorus stock worth over $300,388 and over the last 20 years Luke sold ONCR stock worth over $44,236,178.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Luke Evnin ONCR stock SEC Form 4 insiders trading

Luke has made over 14 trades of the Oncorus stock since 2004, according to the Form 4 filled with the SEC. Most recently Luke bought 151,225 units of ONCR stock worth $2,268,375 on 6 October 2020.

The largest trade Luke's ever made was selling 500,000 units of Oncorus stock on 18 March 2013 worth over $14,220,000. On average, Luke trades about 69,251 units every 192 days since 2004. As of 6 October 2020 Luke still owns at least 2,492,843 units of Oncorus stock.

You can see the complete history of Luke Evnin stock trades at the bottom of the page.

What's Luke Evnin's mailing address?

Luke's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.

Insiders trading at Oncorus

Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin y James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.

What does Oncorus do?

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Luke Evnin stock trades at Pacira BioSciences Inc, Radius Recycling, Rigel Pharmaceuticals, Syndax Pharmaceuticals Inc, Cortexyme Inc, Harpoon Therapeutics y Oncorus

Oncorus executives and stock owners

Oncorus executives and other stock owners filed with the SEC include:

• Stephen W. Harbin,
  COO & Chief of Staff
• Dr. Theodore T. Ashburn M.D., Ph.D.,
  Pres, CEO & Director
• Dr. Theodore T. Ashburn,
  Pres, CEO & Director
• Dr. Christophe Queva Ph.D.,
  Chief Scientific Officer & Sr. VP of Research
• Stephen Harbin,
  COO & Chief of Staff
• Dr. Mitchell H. Finer Ph.D.,
  Co-Founder & Non-Exec. Chairman
• Dr. Mitchell H. Finer,
  Co-Founder & Exec. Chairman
• Chris German,
  Controller
• Brian J. Shea,
  Director of Legal Counsel & Corp. Sec.
• Richard J. Wanstall M.B.A.,
  CFO, Chief Accounting Officer & Treasurer
• Dr. John Mayer Goldberg M.D.,
  Sr. VP of Clinical Devel.
• John McCabe M.B.A.,
  CFO, Treasurer & Sec.
• Scott A Canute,
  Director
• Rick Wanstall,
  CFO and Treasurer
• Theodore Ashburn,
  President and CEO
• Christophe Queva,
  CSO and SVP, Research
• James E Deerfield Mgmt Hif,...,
  
• Luke Evnin,
  Director
• Oncology Impact Fund L.P.On...,
  
• Ansbert Gadicke,
  10% owner
• Mitchell H. Finer,
  Director
• Bio Ventures 2014, L.P.Fole...,
  
• Spencer Nam,
  Director
• Sun States Fund, L.P.Mpm As...,
  
• Stephen Harbin,
  COO and Chief of Staff
• John P. Mc Cabe,
  CFO and Treasurer
• Mary Kay Fenton,
  Director
• Eric Rubin,
  Director
• Barbara Yanni,
  Director
• John Mayer Goldberg,
  Chief Medical Officer
• James E Deerfield Mgmt Hif,...,
  
• Douglas Fambrough,
  Director